US-based middle-market private equity company FFL Partners has finalised an investment in Apex Infusion, a provider of ambulatory infusion therapy services.
The companies have not disclosed the financial specifics and other terms of the transaction.
This latest strategic move is set to enhance Apex Infusion's existing service offerings and geographical presence.
The healthcare organisation also plans to grow its network through strategic acquisitions.
Apex Infusion CEO Moussie Hailemariam said: “We have already begun mapping out areas to expand geographically through de novo locations, as well as strategic acquisitions to build scale.”
Apex Infusion, which was established in 2006 and headquartered in Signal Hill, California, aims to deliver dependable care to patients in their homes or ambulatory settings. It currently has 11 locations across California.
The company's mission is to achieve optimal patient outcomes through professional collaboration with healthcare professionals, including physicians and nurses.
In addition, Apex Infusion offers a range of services including intravenous immunoglobulin, total parental nutrition, speciality infusion, as well as other therapeutic services.
FFL partner Karen Winterhof said: “Apex Infusion is a well-operated infusion provider focused on delivering a high-quality patient and doctor experience.
“We are pleased to work closely with their talented management team as they seek to meet the critical needs of patients with chronic illnesses while building a leading diversified speciality infusion platform.”
FFL Partners has been a thematic investor since 1997, focusing on growth investments in the healthcare and tech-enabled services sectors.
With more than $5bn of cumulative capital commitments, the company is known for partnering with management teams and adopting a high-engagement approach to expedite business growth.
FFL Partners managing partner Chris Harris said: “We believe there’s a significant greenfield de novo and acquisition opportunity, and we expect to deploy more capital to support Apex’s M&A strategy.”
